会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • 항산화 활성을 가지는 퀴논 화합물
    • 항산화활성을가지는퀴논화합물
    • KR100398055B1
    • 2003-09-19
    • KR1020000070105
    • 2000-11-23
    • 한국화학연구원
    • 박노상정영식성철민임희종조보영공재양
    • C07C50/26
    • PURPOSE: Provided is a quinone compound having excellent antioxidant activity, which can be used for preventing aging and curing cancer, diabetes, epilepsy, imbecility, Parkinson's disease, and etc. CONSTITUTION: The quinone compound is represented by the formula 1 and produced from a compound represented by the formula 3, wherein R1 and R2 are independently methyl or methoxy or R1 and R2 are connectively -CH=CH-CH=CH-, R3 is -NH-(CH2)m-R5, -CO2R6, -OH, and etc., R5 is methyl, phenyl, benzyl, and etc., R6 is hydrogen atom or C1-C4 alkyl, X is CH2 or C=O, and n and m are each 0 or an integer of 1-10.
    • 目的:提供一种具有优异的抗氧化活性的醌化合物,其可用于预防衰老和治疗癌症,糖尿病,癫痫,肌无力,帕金森氏症等。组成:醌化合物由式1表示,由 由式3表示的化合物,其中R 1和R 2独立地为甲基或甲氧基或者R 1和R 2连接地为-CH = CH-CH = CH-,R 3为-NH-(CH 2)m -R 5,-CO 2 R 6,-OH, R5是甲基,苯基,苄基等,R6是氢原子或C1-C4烷基,X是CH2或C = O,n和m各自是0或1-10的整数。
    • 9. 发明授权
    • NMDA수용체길항제로작용하는4-(말단치환-알킬아미노)-퀴놀린-2-카복실산유도체
    • 作为NMDA受体拮抗剂起作用的4-(端羟基亚氨基) - 喹啉-2-羧酸衍生物
    • KR100274005B1
    • 2000-12-15
    • KR1019980006276
    • 1998-02-26
    • 한국화학연구원
    • 박노상성철민정영식정용준김란희최진일공재양
    • C07D215/42
    • PURPOSE: Provided are the novel NMDA receptor antagonists, 4-(end-substituted-alkylamine)-quinoline-2-carboxylic acid derivatives and the preparation method thereof. CONSTITUTION: The novel derivatives are represented by the chemical formula 1, where n is 0-10, Nu is either appropriately substituted or unsubstituted arylthio, alkylphosphonate, arylsulfonyl, thiourea, non-aromatic thio, heterocyclic thio, arylphosphonate, heterocycle, alkyl, aryl, cyano, hydroxyl, halogen, arylphosphonate alkylsulfonyl, arylsulfonyl, carbamate, amide, urea, acylurea, sulfonylurea, acylthiourea, sulfonylthiourea, thiocarbamate, amidine, guanidine, imidate, thioimidate, phosphorylamide, sulfonamide or amine groups. The synthetic process contains the following steps: alkylating 5,7-dichlorokynurenic acid methylester with 1,3-dibromopropane; eliminating N-tosyl group with sulfuric acid and substitution of the bromine with NaN3 to make azidomine; reducing with Pd/C to amine compound; converting to the corresponding thioisocyanate and finally hydrolysing the ester group to make the compound of formula 1. The synthetic process of the compound of formula 1, where Nu is substituted arylthio or alkyphosphonate group, comprises the steps of: alkylating 5,7-dichlorokynurenic acid methylester with 1,3-dibromopropane; treating the resultant bromine compound either with arylthio compound to make sulfides or with alkylphosphonates to obtain phosphonate compound; treating these compounds with sulfuric acid to eliminate N-tosyl group and finally hydrolysing them with base to obtain the compound of formula 1. They are effective in the treatment and prevention of the chronic neurodegenerative disease such as epilepsy, Alzheimer's disease, Huntington's and Parkinson's disease and also effective as an analgesic, tranquilizer, treatment agents for depression and psychotic diseases.
    • 目的:提供新型NMDA受体拮抗剂4-(末端取代烷基胺) - 喹啉-2-羧酸衍生物及其制备方法。 构成:新型衍生物由化学式1表示,其中n为0-10,Nu为适当取代或未取代的芳硫基,烷基膦酸酯,芳基磺酰基,硫脲,非芳族硫代,杂环硫基,芳基膦酸酯,杂环,烷基,芳基 氰基,羟基,卤素,芳基膦酸酯烷基磺酰基,芳基磺酰基,氨基甲酸酯,酰胺,脲,酰基脲,磺酰脲,酰基硫脲,磺酰基硫脲,硫代氨基甲酸酯,脒,胍,亚氨酸酯,硫代亚氨酸酯,磷酰胺,磺酰胺或胺基。 合成方法包括以下步骤:用1,3-二溴丙烷将5,7-二氯喹诺酮酸甲酯烷基化; 用硫酸除去N-甲苯磺酰基,用NaN 3取代溴,得到叠氮基; 用Pd / C还原为胺化合物; 转化为相应的硫代异氰酸酯,最后水解酯基以制备式1的化合物。其中Nu为取代的芳硫基或亚膦酸酯基团的式1化合物的合成方法包括以下步骤:将5,7-二氯喹诺酮酸 甲基酯与1,3-二溴丙烷; 用芳硫基化合物处理所得溴化合物以制备硫化物或与烷基膦酸酯反应得到膦酸酯化合物; 用硫酸处理这些化合物以消除N-甲苯磺酰基,最后用碱水解它们,得到式1化合物。它们有效治疗和预防慢性神经变性疾病如癫痫,阿尔茨海默病,亨廷顿病和帕金森病 并且作为抑郁和精神病的止痛剂,镇定剂,治疗剂也是有效的。